Syngene International gets USFDA EIR for Bengaluru GMP manufacturing facilities
Karnataka: Syngene International has announced that the Company has received Establishment Inspection Report (EIR) from US Food and Drugs Administration (USFDA) for its GMP manufacturing facilities located at Biocon Park, SEZ, Bengaluru.
The EIR concluded the inspectional outcome as Voluntary Action Indicated (VAI). VAI which means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action
"The US FDA has reviewed and accepted Syngene’s responses and Corrective and Preventive Action (CAPA) plans submitted in response to the inspectional findings. Syngene will continue to provide periodic updates to the USFDA on the progress of corrective actions submitted to the agency. We remain committed to maintaining the highest standards of regulatory compliance and this outcome will not have any adverse impact on the Company’s financials or operations," Syngene stated in a BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.